Comparative Pharmacology
Head-to-head clinical analysis: TAVIST versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAVIST versus TAVIST 1.
TAVIST vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
1.34 mg orally twice daily; maximum 8.04 mg/day.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine
Antihistamine